Next Article in Journal
Urinary Metabolomic Profiling after Administration of Corydalis Tuber and Pharbitis Seed Extract in Healthy Korean Volunteers
Next Article in Special Issue
Nanoparticles as a Tool in Neuro-Oncology Theranostics
Previous Article in Journal
Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total
 
 
Review
Peer-Review Record

Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy

Pharmaceutics 2021, 13(4), 520; https://doi.org/10.3390/pharmaceutics13040520
by Tianqi Wang 1, Yusuke Suita 2, Saradha Miriyala 2, Jordan Dean 1, Nikos Tapinos 2,3,* and Jie Shen 1,4,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Pharmaceutics 2021, 13(4), 520; https://doi.org/10.3390/pharmaceutics13040520
Submission received: 24 February 2021 / Revised: 4 April 2021 / Accepted: 5 April 2021 / Published: 9 April 2021
(This article belongs to the Special Issue Particle Engineering for Drug Delivery Applications)

Round 1

Reviewer 1 Report

Comments 1. Can author give more highlight on Cancer vaccine. It could be better if he can summarize the data in Table also. 2. What is the role of lipid in cancer treatment. add in one para. 3. Mention the list of lipids reported for anticancer property with their concentration reported. 4. The lipids NPs having many drawbacks as delivery. How the author overcome for cancer delivery. 5. Author have written in manuscript as lipid coated NPs.....Write the name of lipid. 6. Can author add the combination therapy for bioactive with synthetic drug as lipid based delivery for cancer therapy. 7. Cite the following a. Molecular pharmaceutics 13 (11), 3773-3782. b. International Journal of Biological Macromolecules 116, 1260-1267. c. Journal of Drug Delivery Science and Technology, 102198

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

I read with great interest the review by Wang and co-authors describing the use of lipid-based nanoparticles in cancer therapy. The review is well written and organized, describing the most remarkable nanoparticles for cancer therapy in preclinical development.  References are up-to-date and a really interesting introduction is given to the main aspect of cancer immunotherapy. The different types of lipid-nanoparticles are really well described and properly grouped. The review is overall attractive and interesting to the reader. In my opinion there is only a minor change to introduce to further improve the quality of the review making it acceptable for publication:

1) The authors should improve chapter 3 more widely describing the advantages given by nanopaticles in cancer therapy. The main concept are described but should be widely detailed.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop